Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01781741 · ClinicalTrials.gov registry record · Early Phase 1
Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer
A Early Phase 1 study of Stage IV Non-small Cell Lung Cancer and Stage IIIB Non-small Cell Lung Cancer, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT01781741 is a Early Phase 1 study of Stage IV Non-small Cell Lung Cancer and Stage IIIB Non-small Cell Lung Cancer that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 10 participants, below the 689-participant average among 23 other Stage IV Non-small Cell Lung Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01781741, a Early Phase 1 study of Stage IV Non-small Cell Lung Cancer and Stage IIIB Non-small Cell Lung Cancer, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot clinical trial studies stereotactic body radiation therapy after surgery in treating patients with stage III-IV non-small cell lung cancer. Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Lymphadenectomy may remove tumor cells that have spread to nearby lymph nodes in patients with non-small cell lung cancer. Giving stereotactic body radiation therapy after lymphadenectomy may kill any tumor cells that remain after surgery.
Conditions Studied
Interventions
- OTHER quality-of-life assessment
- COMBINATION_PRODUCT therapeutic lymphadenectomy (TEMLA) and Stereotactic Body radiation therapy (SBRT)
Study Locations (1)
New York
- Roswell Park Cancer Institute - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2013-03-06 |
| Est. Completion | 2020-10-14 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01781741
The ClinicalTrials.gov registry entry for NCT01781741 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 689-participant average among 23 other Stage IV Non-small Cell Lung Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Stage IV Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which quality-of-life assessment is the first listed.
NCT01781741 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01781741 about?
NCT01781741 is a clinical study titled "Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer". This pilot clinical trial studies stereotactic body radiation therapy after surgery in treating patients with stage III-IV non-small cell lung cancer. Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Lymphadenectomy may remove tu...
What is the current status of trial NCT01781741?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2013-03-06. Estimated completion is 2020-10-14.
What conditions does trial NCT01781741 study?
This clinical trial studies the following conditions: Stage IV Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT01781741?
The interventions under investigation include: quality-of-life assessment (OTHER), therapeutic lymphadenectomy (TEMLA) and Stereotactic Body radiation therapy (SBRT) (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT01781741?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01781741 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Non-small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ruxolitinib for Cancer Cachexia
ACTIVE NOT RECRUITING · Early Phase 1
-
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
RECRUITING · Phase 1
-
Patient-centered, Optimal Integration of Survivorship and Palliative Care
RECRUITING · NA
-
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
RECRUITING · NA
-
Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer
RECRUITING · NA
-
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Stage IV Non-small Cell Lung Cancer
All registered trials for this condition
Stage IIIB Non-small Cell Lung Cancer
All registered trials for this condition
New York
All trials with a study site in New York
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.